Imfinzi (Durvalumab) for Lung Cancer

Overview
Imfinzi is a prescription medication approved by the U.S. Food and Drug Administration (FDA) for treating extensive small-cell lung cancer and late-stage (locally advanced or metastatic) non-small cell lung cancers that have high programmed death-cell (PD-1) expression and have already been treated with chemotherapy and radiation. Imfinzi is sometimes prescribed with etoposide and either carboplatin or cisplatin. Imfinzi is also known by its drug name, durvalumab.

PD-1 is a protein that helps cancer cells evade the immune system. Imfinzi is a genetically engineered antibody (protein) designed to bind with PD-1 expressed on tumor cells and tumor-infiltrating immune cells. Imfinzi is believed to work by allowing the immune system to identify and destroy cancer cells.

How do I take it?
Imfinzi is given as an intravenous infusion.

Imfinzi comes in a single-dose vial.

Side effects
The FDA-approved label for Imfinzi lists common side effects including cough, fatigue, pneumonia, shortness of breath, rash, and upper respiratory tract infections.

Rare but serious side effects listed for Imfinzi can include fetal harm, immune-mediated adverse reactions, and infusion reactions.

For more details about this treatment, visit:

Imfinzi — AstraZeneca
https://www.imfinzi.com

Immunotherapy for Non-small Cell Lung Cancer — Cancer
https://www.cancer.org/cancer/lung-cancer/treat...